NASDAQ:TSRO - TESARO Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$39.24 -0.99 (-2.46 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$39.24
Today's Range$39.0951 - $40.49
52-Week Range$38.40 - $137.25
Volume1.39 million shs
Average Volume1.53 million shs
Market Capitalization$2.21 billion
P/E Ratio-4.28
Dividend YieldN/A
TESARO logoTesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd., as well as Genentech. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Receive TSRO News and Ratings via Email

Sign-up to receive the latest news and ratings for TSRO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio3.74
Current Ratio4.02
Quick Ratio3.56


Trailing P/E Ratio-4.28
Forward P/E Ratio-3.91
P/E GrowthN/A

Sales & Book Value

Annual Sales$223.33 million
Price / Sales9.63
Cash FlowN/A
Price / CashN/A
Book Value$4.58 per share
Price / Book8.57


EPS (Most Recent Fiscal Year)($9.17)
Net Income$-496,120,000.00
Net Margins-193.42%
Return on Equity-177.92%
Return on Assets-71.46%


Outstanding Shares54,820,000
Market Cap$2,205.55

TESARO (NASDAQ:TSRO) Frequently Asked Questions

What is TESARO's stock symbol?

TESARO trades on the NASDAQ under the ticker symbol "TSRO."

How were TESARO's earnings last quarter?

TESARO Inc (NASDAQ:TSRO) announced its earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($2.98) EPS for the quarter, missing analysts' consensus estimates of ($2.56) by $0.42. The biopharmaceutical company had revenue of $49.74 million for the quarter, compared to analysts' expectations of $56.34 million. TESARO had a negative net margin of 193.42% and a negative return on equity of 177.92%. The business's revenue was up 1520.2% compared to the same quarter last year. During the same quarter last year, the business earned ($2.55) earnings per share. View TESARO's Earnings History.

When is TESARO's next earnings date?

TESARO is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for TESARO.

What price target have analysts set for TSRO?

20 analysts have issued twelve-month target prices for TESARO's shares. Their forecasts range from $48.00 to $199.00. On average, they expect TESARO's share price to reach $106.20 in the next year. This suggests a possible upside of 170.6% from the stock's current price. View Analyst Ratings for TESARO.

What is the consensus analysts' recommendation for TESARO?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TESARO in the last year. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about TESARO stock?

Here are some recent quotes from research analysts about TESARO stock:
  • 1. According to Zacks Investment Research, "TESARO's Zejula has performed well since its approval in early 2017, gaining majority of U.S. ovarian cancer market share in the PARP inhibitor segment. The drug also has bright prospects, given the tremendous demand for PARP inhibitors. Moreover, collaborations with several large pharma companies for the development of Zejula generates a cash flow stream for TESARO and enables sharing of R&D costs. TESARO’s efforts for label expansion of Zejula are also encouraging. However, TESARO is heavily dependent on Zejula for growth, which concerns us. Meanwhile, competition in the PARP inhibitor segment is rising with two other approved drugs and several companies developing their candidates. TESARO’s shares have underperformed the industry so far this year. Estimate movement has been mixed ahead of the company’s Q2 earnings release. TESARO has a negative record of earnings surprises in recent quarters." (7/17/2018)
  • 2. Cann analysts commented, "We believe this analysis of TOPACIO continues to support our outlook for the use of Zejula in ovarian cancer. The ASCO presentation was to a very large audience, which we believe will greatly increase awareness of these data. As a result, we are maintaining our current sales estimates for Zejula. Investigators stated that Zejula in combination with a PD-1 inhibitor provides clinical benefit in patients with platinum- resistant and platinum-refractory disease." (6/4/2018)
  • 3. HC Wainwright analysts commented, "Updates to Varubi’s Label; Reiterate Buy and $158 Price Target Prescribing information update, no products being recalled. After the close on January 12, TESARO announced that it has updated the Varubi injectable emulsion package insert in collaboration with the FDA. The changes to the label include modifications to the Contradictions, Warnings and Precuations, and Adverse Reactions section to inclde anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions associated with the use of Varubi injectable emulsion. The company indicated that anaphylaxis, anaphylactic shock and other hypersensitivity reactions have been reported in the postmarketing setting, with some cases requiring hospitalization. These side effects were noted during or soon after the infusion of Varubi, with most reactions observed during the first few minutes of administration." (1/12/2018)

Are investors shorting TESARO?

TESARO saw a decline in short interest during the month of June. As of June 15th, there was short interest totalling 9,507,909 shares, a decline of 13.3% from the May 31st total of 10,971,039 shares. Based on an average daily volume of 2,138,606 shares, the short-interest ratio is presently 4.4 days. Approximately 24.9% of the shares of the company are short sold. View TESARO's Current Options Chain.

Who are some of TESARO's key competitors?

Who are TESARO's key executives?

TESARO's management team includes the folowing people:
  • Mr. Leon O. Moulder Jr., Co-Founder, CEO & Director (Age 61)
  • Dr. Mary Lynne Hedley, Co-Founder, Pres, COO & Director (Age 55)
  • Mr. Timothy R. Pearson, Exec. VP & CFO (Age 50)
  • Dr. Martin H. Huber Jr., Sr. VP & Chief Medical Officer (Age 58)
  • Mr. Orlando Oliveira, Sr. VP & GM of International (Age 42)

Has TESARO been receiving favorable news coverage?

Headlines about TSRO stock have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TESARO earned a coverage optimism score of 0.04 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 47.00 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are TESARO's major shareholders?

TESARO's stock is owned by a number of of institutional and retail investors. Top institutional investors include Creative Planning (0.16%), Fred Alger Management Inc. (0.14%), Essex Investment Management Co. LLC (0.03%) and Xact Kapitalforvaltning AB (0.01%). Company insiders that own TESARO stock include David M Mott, Edward C English, Enterprise Associates 13 L New, Grant C Bogle, James O Armitage, Jeffrey H Hanke, Lawrence M Alleva, Leon O Moulder Jr, Martin H Jr Huber, Mary Lynne Hedley, Orlando Oliveira, Peter J Barris and Timothy R Pearson. View Institutional Ownership Trends for TESARO.

Which major investors are buying TESARO stock?

TSRO stock was bought by a variety of institutional investors in the last quarter, including Creative Planning, Fred Alger Management Inc., Essex Investment Management Co. LLC and Xact Kapitalforvaltning AB. Company insiders that have bought TESARO stock in the last two years include David M Mott, Enterprise Associates 13 L New, Leon O Moulder Jr and Peter J Barris. View Insider Buying and Selling for TESARO.

How do I buy shares of TESARO?

Shares of TSRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TESARO's stock price today?

One share of TSRO stock can currently be purchased for approximately $39.24.

How big of a company is TESARO?

TESARO has a market capitalization of $2.21 billion and generates $223.33 million in revenue each year. The biopharmaceutical company earns $-496,120,000.00 in net income (profit) each year or ($9.17) on an earnings per share basis. TESARO employs 715 workers across the globe.

How can I contact TESARO?

TESARO's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 339-970-0900.

MarketBeat Community Rating for TESARO (NASDAQ TSRO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  513 (Vote Outperform)
Underperform Votes:  358 (Vote Underperform)
Total Votes:  871
MarketBeat's community ratings are surveys of what our community members think about TESARO and other stocks. Vote "Outperform" if you believe TSRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TSRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by Staff

Featured Article: What does EPS mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.